entecavir or tenofovir or tenofovir alafenamide + interferon

This combination regimen involves the use of a nucleoside or nucleotide analog (NA)—specifically entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide—in conjunction with interferon (typically pegylated interferon-alpha). The regimen is primarily utilized in the management of chronic hepatitis B (CHB). The NAs act as potent inhibitors of the HBV DNA polymerase, effectively suppressing viral replication by acting as chain terminators during reverse transcription. Interferon provides complementary immunomodulatory effects, enhancing the host's innate and adaptive immune responses to promote the clearance of HBV-infected hepatocytes. Clinical research, including studies led by Zhongshan Hospital (Xiamen) and Fudan University, explores this combination's efficacy in achieving higher rates of HBsAg seroclearance (functional cure) and reducing the long-term risk of hepatocellular carcinoma (HCC) in high-risk patients compared to NA monotherapy.

Other names

NAs + IFNNucleoside analogs + interferonNA + IFN regimen